Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice

[1]  T. Rolph,et al.  FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases , 2020, Frontiers in Endocrinology.

[2]  Robert C. G. Martin,et al.  Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling , 2020, Theranostics.

[3]  W. S. Denney,et al.  AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients , 2020, Cell reports. Medicine.

[4]  Yue Wang,et al.  Modulation of the Astrocyte-Neuron Lactate Shuttle System contributes to Neuroprotective action of Fibroblast Growth Factor 21 , 2020, Theranostics.

[5]  G. Mitchell,et al.  Deficiency of 3‐hydroxybutyrate dehydrogenase (BDH1) in mice causes low ketone body levels and fatty liver during fasting , 2020, Journal of inherited metabolic disease.

[6]  Y. Hattori.  Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization , 2020, Heart Failure Reviews.

[7]  G. Church,et al.  A single combination gene therapy treats multiple age-related diseases , 2019, Proceedings of the National Academy of Sciences.

[8]  A. Giménez-Cassina,et al.  Fibroblast growth Factor-21 promotes ketone body utilization in neurons through activation of AMP-dependent kinase , 2019, Molecular and Cellular Neuroscience.

[9]  K. Cusi,et al.  Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. , 2019, The Journal of clinical endocrinology and metabolism.

[10]  S. Burgess,et al.  Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver. , 2019, JCI insight.

[11]  M. Patti,et al.  SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. , 2019, JCI insight.

[12]  M. Goodson,et al.  Fibroblast Growth Factor-21 Controls Dietary Protein Intake in Male Mice. , 2019, Endocrinology.

[13]  B. Neuschwander‐Tetri,et al.  Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial , 2018, The Lancet.

[14]  F. Mulero,et al.  FGF21 gene therapy as treatment for obesity and insulin resistance , 2018, EMBO molecular medicine.

[15]  A. Mithal,et al.  Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial) , 2018, Diabetes Care.

[16]  R. DiMarchi,et al.  Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity , 2018, Molecular metabolism.

[17]  Jing Xu,et al.  FGF21 acts as a negative regulator of bile acid synthesis. , 2018, The Journal of endocrinology.

[18]  J. Flier,et al.  Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet , 2018, Molecular metabolism.

[19]  S. Park,et al.  LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice , 2018, PloS one.

[20]  E. Pardon,et al.  Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling , 2018, Nature.

[21]  Shuhong Zhao,et al.  Fibroblast Growth Factor 21 Promotes C2C12 Cells Myogenic Differentiation by Enhancing Cell Cycle Exit , 2017, BioMed research international.

[22]  Meijuan Huang,et al.  Technical Improvement and Application of Hydrodynamic Gene Delivery in Study of Liver Diseases , 2017, Front. Pharmacol..

[23]  Shuhong Zhao,et al.  Fibroblast Growth Factor 21 (FGF21) Promotes Formation of Aerobic Myofibers via the FGF21‐SIRT1‐AMPK‐PGC1α Pathway , 2017, Journal of cellular physiology.

[24]  Xiaolong Lin,et al.  Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues , 2017, Biomedical reports.

[25]  Matthew J. Potthoff,et al.  FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms. , 2017, Cell metabolism.

[26]  Yuan Zhang,et al.  Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action , 2016, EBioMedicine.

[27]  R. Kim,et al.  A Fibroblast Growth Factor 21–Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease , 2016, Molecular Pharmacology.

[28]  Mengwei Zang,et al.  Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice , 2016, Hepatology.

[29]  Robert C. G. Martin,et al.  Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice. , 2016, American journal of cancer research.

[30]  S. Salatino,et al.  Skeletal muscle PGC‐1α modulates systemic ketone body homeostasis and ameliorates diabetic hyperketonemia in mice , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  J. Inoue,et al.  Fibroblast growth factor 21 induction by activating transcription factor 4 is regulated through three amino acid response elements in its promoter region , 2016, Bioscience, biotechnology, and biochemistry.

[32]  Jeffrey R. Chabot,et al.  A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. , 2016, Cell metabolism.

[33]  Daiwen Chen,et al.  Regulation of fibroblast growth factor 15/19 and 21 on metabolism: in the fed or fasted state , 2016, Journal of Translational Medicine.

[34]  T. Rolph,et al.  FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance , 2015, Scientific Reports.

[35]  M. Véniant,et al.  Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue. , 2015, Cell metabolism.

[36]  M. Mohammadi,et al.  FGF21 mediates alcohol-induced adipose tissue lipolysis by activation of systemic release of catecholamine in mice[S] , 2015, Journal of Lipid Research.

[37]  S. Kliewer,et al.  Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21 , 2015, Trends in Endocrinology & Metabolism.

[38]  D. Schuppan,et al.  Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. , 2014, Gastroenterology.

[39]  D. Moller,et al.  FGF21-based pharmacotherapy – potential utility for metabolic disorders , 2014, Trends in Endocrinology & Metabolism.

[40]  F. Villarroya,et al.  Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients , 2014, International Journal of Obesity.

[41]  L. Guarente,et al.  Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. , 2014, Gastroenterology.

[42]  Margaret S. Wu,et al.  Downstream Signaling Pathways in Mouse Adipose Tissues Following Acute In Vivo Administration of Fibroblast Growth Factor 21 , 2013, PloS one.

[43]  H. Fu,et al.  The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. , 2013, Cell metabolism.

[44]  Randy L. Johnson,et al.  Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress , 2013, BMC Gastroenterology.

[45]  M. Martínez-Chantar,et al.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. , 2010, Gastroenterology.

[46]  R. Wanders,et al.  A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation , 2010, Journal of Inherited Metabolic Disease.

[47]  M. Konishi,et al.  Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. , 2009, Endocrinology.

[48]  D. Moller,et al.  Fibroblast growth factor 21 corrects obesity in mice. , 2008, Endocrinology.

[49]  Masashi Suzuki,et al.  betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. , 2008, Molecular endocrinology.

[50]  H. Tilg,et al.  Inflammatory Mechanisms in the Regulation of Insulin Resistance , 2008, Molecular medicine.

[51]  S. Kliewer,et al.  Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21* , 2007, Journal of Biological Chemistry.

[52]  S. Kliewer,et al.  Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. , 2007, Cell metabolism.

[53]  S. McCall,et al.  Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis , 2007, Hepatology.

[54]  S. Kahn,et al.  Mechanisms linking obesity to insulin resistance and type 2 diabetes , 2006, Nature.

[55]  W. Mckeehan,et al.  Forced expression of hepatocyte‐specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis , 2006, Molecular carcinogenesis.

[56]  G. Targher,et al.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. , 2005, Diabetes.

[57]  J. Gromada,et al.  FGF-21 as a novel metabolic regulator. , 2005, The Journal of clinical investigation.

[58]  E. Bruckert,et al.  Systemic low-grade inflammation is related to both circulating and adipose tissue TNFα, leptin and IL-6 levels in obese women , 2004, International Journal of Obesity.

[59]  S. Hughes,et al.  Differential Expression of the Fibroblast Growth Factor Receptor (FGFR) Multigene Family in Normal Human Adult Tissues , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[60]  R. Pais,et al.  Fatty liver and renal function impairment - Time for awareness? , 2017, Journal of hepatology.

[61]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.